Increased expression of CCAAT/enhancer-binding protein beta in proliferative inflammatory atrophy of the prostate: Telation with the expression of COX-2, the androgen receptor, and presence of focal chronic inflammation

Prostate

Volumn 67, Issue 11, 2007, Pages 1238-1246

  Wang, Wanzhong ^a   Bergh, Anders ^b   Damber, Jan Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Androgen receptor; CCAAT enhancer binding protein beta; Chronic inflammation; COX 2; Proliferative inflammatory atrophy

Indexed keywords

ANDROGEN RECEPTOR; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CELL DENSITY; CHRONIC INFLAMMATION; CLINICAL ARTICLE; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN EXPRESSION; T LYMPHOCYTE;

AGED; ATROPHY; BIOLOGICAL MARKERS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CYCLOOXYGENASE 2; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROSTATITIS; RECEPTORS, ANDROGEN;

EID: 34547655422     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20595     Document Type: Article

References (51)

1. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-67.
2. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis 2005;26:1170-1181.
3. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60:78-83.
4. Patel DA, Bock CH, Schwartz K, Wenzlaff AS, Demers RY, Severson RK. Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: A case-control study in Wayne County, Michigan. Cancer Causes Control 2005;16:263-273.
5. Perron L, Bairati I, Moore L, Meyer F, Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003;106:409-415.
6. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S. The influence of chronic inflammation in prostatic carcinogenesis: A 5-year followup study. J Urol 2006;176:1012-1016.
7. Meirelles LR, Billis A, Cotta AC, Nakamura RT, Caserta NM, Prando A. Prostatic atrophy: Evidence for a possible role of local ischemia in its pathogenesis. Int Urol Nephrol 2002;34:345-350.
8. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-1992.
9. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland; Neoplastic precursor or innocent bystander? Am J Pathol 2001;158:1767-1773.
10. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000;56:828-832.
11. Nelson CP, Kidd LC, Sauvageot J, Isaacs WB, De Marzo AM, Groopman JD, Nelson WG, Kensler TW. Protection against 2-hydroxyamino-1-methyl-6- phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res 2001;61:103-109.
12. Tsujimoto Y, Takayama H, Nonomura N, Okuyama A, Aozasa K. Postatrophic hyperplasia of the prostate in Japan: Histologic and immunohistochemical features and p53 gene mutation analysis. Prostate 2002;52:279-287.
13. Faith D, Han S, Lee DK, Friedl A, Hicks JL, De Marzo AM, Jarrard DF. p16 Is upregulated in proliferative inflammatory atrophy of the prostate. Prostate 2005;65:73-82.
14. Anton RC, Kattan MW, Chakraborty S, Wheeler TM. Postatrophic hyperplasia of the prostate: Lack of association with prostate cancer. Am J Surg Pathol 1999;23:932-936.
15. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:8617-8623.
16. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004;61:60-72.
17. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005;11:3250-3256.
18. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-78.
19. Wu KK. Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot Essent Fatty Acids 2005;72:89-93.
20. Chen JJ, Huang WC, Chen CC. Transcriptional regulation of cyclooxygenase-2 in response to proteasome inhibitors involves reactive oxygen species-mediated signaling pathway and recruitment of CCAAT/enhancer-binding protein delta and CREB-binding protein. Mol Biol Cell 2005;16:5579-5591.
21. Saunders MA, Sansores-Garcia L, Gilroy DW, Wu KK. Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. J Biol Chem 2001;276:18897-18904.
22. Zhu Y, Saunders MA, Yeh H, Deng WG, Wu KK. Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins. J Biol Chem 2002;277:6923-6928.
23. Cieslik KA, Zhu Y, Shtivelband M, Wu KK. Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer-binding protein beta activation and cyclooxygenase-2 expression by salicylate. J Biol Chem 2005;280:18411-18417.
24. Wu KK, Liou JY, Cieslik K. Transcriptional Control of COX-2 via C/EBPbeta. Arterioscler Thromb Vasc Biol 2005;25:679-685.
25. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: Structure, function and regulation. Biochem J 2002;365:561-575.
26. Foka P, Irvine SA, Kockar F, Ramji DP. Interleukin-6 represses the transcription of the CCAAT/enhancer binding protein-alpha gene in hepatoma cells by inhibiting its ability to autoactivate the proximal promoter region. Nucleic Acids Res 2003;31:6722-6732.
27. Mantena SR, Kannan A, Cheon YP, Li Q, Johnson PF, Bagchi IC, Bagchi MK. C/EBPbeta is a critical mediator of steroid hormone-regulated cell proliferation and differentiation in the uterine epithelium and stroma. Proc Natl Acad Sci U S A 2006;103:1870-1875.
28. Seagroves TN, Krnacik S, Raught B, Gay J, Burgess-Beusse B, Darlington GJ, Rosen JM. C/EBPbeta, but not C/EBPalpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev 1998;12:1917-1928.
29. Dearth LR, Hutt J, Sattler A, Gigliotti A, DeWille J. Expression and function of CCAAT/enhancer binding proteinbeta (C/EBPbeta) LAP and LIP isoforms in mouse mammary gland, tumors and cultured mammary epithelial cells. J Cell Biochem 2001;82:357-370.
30. Grimm SL, Rosen JM. The role of C/EBPbeta in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003;8:191-204.
31. Rask K, Thorn M, Ponten F, Kraaz W, Sundfeldt K, Hedin L, Enerback S. Increased expression of the transcription factors CCAAT-enhancer binding protein-beta (C/EBBeta) and C/EBzeta (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer 2000;86:337-343.
32. Regalo G, Canedo P, Suriano G, Resende C, Campos M, Oliveira M, Figueiredo C, Rodrigues-Pereira P, Blin N, Seruca R, Carneiro F, Machado J. C/EBPbeta is over-expressed in gastric carcinogenesis and is associated with COX-2 expression. J Pathol 2006;210:398-404.
33. Sundfeldt K, Ivarsson K, Carlsson M, Enerback S, Janson PO, Brannstrom M, Hedin L. The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: Specific increase in C/EBPbeta during epithelial tumour progression. Br J Cancer 1999;79:1240-1248.
34. Milne AN, Carvalho R, Morsink FM, Musler AR, de Leng WW, Ristimaki A, Offerhaus GJ. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol 2006;19:564-572.
35. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo AM. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003;162:1529-1537.
36. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002;26:1161-1168.
37. Oya M, Horiguchi A, Mizuno R, Marumo K, Murai M. Increased activation of CCAAT/enhancer binding protein-beta correlates with the invasiveness of renal cell carcinoma. Clin Cancer Res 2003;9:1021-1027.
38. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farree X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Lucia MS. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006;30:1281-1291.
39. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003;23:3825-3835.
40. Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004;171:S59-S63.
41. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005;14:390-396.
42. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005;97:975-980.
43. Narayanan BA, Narayanan NK, Pttman B, Reddy BS. Adenocarcina of the mouse prostate growth inhibition by celecoxib: Downregulation of transcription factors involved in COX-2 inhibition. Prostate 2006;66:257-265.
44. Gorgoni B, Caivano M, Arizmendi C, Poli V. The transcription factor C/EBPbeta is essential for inducible expression of the cox-2 gene in macrophages but not in fibroblasts. J Biol Chem 2001;276:40769-40777.
45. Cieslik K, Zhu Y, Wu KK. Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway. J Biol Chem 2002;277:49304-49310.
46. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002;1:113-121.
47. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000;164:800-805.
48. Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998;34:251-258.
49. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A, Jarrard DF. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 2000;60:3623-3630.
50. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB, Nassif N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 1998;58:5310-5314.
51. Sigala S, Tognazzi N, Rizzetti MC, Faraoni I, Missale C, Bonmassar E, Spano P. Nerve growth factor induces the re-expression of functional androgen receptors and p75(NGFR) in the androgen-insensitive prostate cancer cell line DU145. Eur J Endocrinol 2002;147:407-415.